BeiGene Ltd header image

BeiGene Ltd

BGNE

Equity

ISIN null / Valor 30165310

NASDAQ (2026-10-30)
USD 370.33-0.33%

BeiGene Ltd
UMushroom community rating:

star star star star star
4.00 2 votes No rating yet
NegativeNeutralPositive

About company

BeiGene Ltd is a Beijing‑founded, research‑driven biopharmaceutical company that develops, manufactures and commercializes cancer treatments worldwide. The company concentrates on oncology, advancing a pipeline of targeted small molecules, monoclonal antibodies and other immuno‑oncology assets through global clinical trials while building commercial operations in major markets including China, the United States and Europe. Its marketed products include the BTK inhibitor zanubrutinib and the anti‑PD‑1 antibody tislelizumab, and it pursues both in‑house development and collaborations to expand indications and geographic reach. BeiGene is vertically integrated across discovery, development and production capacities and is publicly traded on U.S. and Hong Kong exchanges.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

20.2%1Y
98.5%3Y
3.53%5Y

Performance

35.0%1Y
43.6%3Y
54.4%5Y

Volatility

Market cap

42107 M

Market cap (USD)

Daily traded volume (Shares)

292,821

Daily traded volume (Shares)

1 day high/low

185.01 / 179.74

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

2 votes
Performance:
starstarstarstarstar
4.83
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
3.17
Nature:
starstarstarstarstar
2.33
Josh Tompsett
UK, 21 Oct 2026
star star star star star
This is a good instrument, as it there is an ever-present requirement for the healthcare at a societal level, as people continue to age, and disease can be transmitted with increasing ease.
Christian Bircher
Switzerland, 30 Mar 2025
star star star star star
Stabile Performance

EQUITIES OF THE SAME SECTOR

Omnicell Inc
Omnicell Inc Omnicell Inc Valor: 1275961
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.62%USD 36.65
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc Valor: 25419823
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%USD 37.41
Trupanion Inc
Trupanion Inc Trupanion Inc Valor: 24738737
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.20%USD 30.13
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.43%SEK 276.80
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.45%SEK 490.20
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited Dr. Lal PathLabs Limited Valor: 30691066
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.37%INR 1,906.30
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.05%USD 16.03
Elekta AB
Elekta AB Elekta AB Valor: 613625
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.05%SEK 59.70
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.69%SEK 317.20
Essity AB
Essity AB Essity AB Valor: 36846754
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%SEK 279.50